Related references
Note: Only part of the references are listed.Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma
Christine Damm-Welk et al.
HAEMATOLOGICA (2020)
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial
Fabian Knoerr et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
Lara Mussolin et al.
CANCERS (2020)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma
Yuka Iijima-Yamashita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Nina Prokoph et al.
CANCERS (2018)
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Franco Locatelli et al.
LANCET HAEMATOLOGY (2018)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Barbara Pro et al.
BLOOD (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Anaplastic large cell lymphoma in paediatric and young adult patients
Suzanne D. Turner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Andrew B. Waight et al.
PLOS ONE (2016)
Advanced Stage Anaplastic Large Cell Lymphoma in Children and Adolescents: Results of ANHL0131, a Randomized Phase III Trial of APO Versus a Modified Regimen With Vinblastine: A Report From the Children's Oncology Group
Sarah Alexander et al.
PEDIATRIC BLOOD & CANCER (2014)
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
Anas Younes et al.
LANCET ONCOLOGY (2013)
Anaplastic Large Cell Lymphoma in Children and Adolescents
Eric J. Lowe et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2013)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood
Marta Pillon et al.
PEDIATRIC BLOOD & CANCER (2012)
Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study
Willi Woessmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study
Laurence Lamant et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety Assessment of Intensive Induction Therapy in Childhood Anaplastic Large Cell Lymphoma: Report of the ALCL99 Randomised Trial
Grazyna Wrobel et al.
PEDIATRIC BLOOD & CANCER (2011)
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial
Marie-Cecile Le Deley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma
Christine Damm-Welk et al.
BLOOD (2007)
Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents -: a Berlin-Frankfurt-Munster group report
W Woessmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation:: a genetic and pathological correlation
SL Perkins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Advanced-stage large-cell lymphoma in children and adolescents: Results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: A Pediatric Oncology Group phase III trial
JH Laver et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens
DM Williams et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - A report from the French Society of Pediatric Oncology
L Brugieres et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
